How adoption of new pharmaceuticals can impact US health system reimbursement under alternative payment models

This is the title of a new paper I have out today at JMCP with co-authors Shanshan Wang, Jaehong Kim, Slaven Sikirica, and Alexander Sandhu with the subtitle “An economic model measuring the impact of sotagliflozin among patients with heart failure and diabetes“. The abstract is below: BACKGROUND: Heart failure (HF) is among the leading…

Cost–effectiveness of sotagliflozin for the treatment of patients with diabetes and recent worsening heart failure

That is the title of my article with Jaehong Kim, Shanshan Wang and Slaven Sikirica in the Journal of Comparative Effectiveness Research. The abstract is below. Aim: To assesses the cost–effectiveness of sotagliflozin for the treatment of patients hospitalized with heart failure and comorbid diabetes.  Materials & methods: A de novo cost–effectiveness model with a Markov structure was created…